Longeveron Licenses Issued US Patent For Stem Cell Technology From University Of Miami

• Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of Miami
• New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)
• New technology substantially advances Longeveron's repertoire of stem cell therapy technologies
• Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas

MIAMI, July 21, 2025 (GLOBE NEWSWIRE) --  Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that it has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition of matter patent protects unique induced pluripotent derived cardiomyogenic cells that have widespread therapeutic indications for heart diseases. The stem/precursor cells protected by this patent are obtained by deriving cells that bear a cell surface receptor known as the GHRH-Receptor. These cells are uniquely able to differentiate into human cardiac muscle cells and have the potential to be safer than existing strategies to derive new cardiac heart muscle cells.